Pioneer Investment Management Inc. reduced its stake in Nevro Corp. (NYSE:NVRO) by 33.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 41,612 shares of the medical equipment provider’s stock after selling 20,803 shares during the period. Pioneer Investment Management Inc. owned 0.14% of Nevro Corp. worth $3,097,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the company. Fortaleza Asset Management Inc. purchased a new position in shares of Nevro Corp. during the first quarter valued at approximately $164,000. Tower Research Capital LLC TRC boosted its position in shares of Nevro Corp. by 118.8% in the first quarter. Tower Research Capital LLC TRC now owns 1,943 shares of the medical equipment provider’s stock valued at $182,000 after buying an additional 1,055 shares in the last quarter. Ameritas Investment Partners Inc. purchased a new position in shares of Nevro Corp. during the first quarter valued at approximately $194,000. US Bancorp DE boosted its position in shares of Nevro Corp. by 412.4% in the second quarter. US Bancorp DE now owns 2,608 shares of the medical equipment provider’s stock valued at $194,000 after buying an additional 2,099 shares in the last quarter. Finally, Inspirion Wealth Advisors LLC purchased a new position in shares of Nevro Corp. during the second quarter valued at approximately $205,000.

Shares of Nevro Corp. (NYSE NVRO) opened at 82.34 on Tuesday. The company’s market capitalization is $2.42 billion. The firm’s 50-day moving average is $82.51 and its 200 day moving average is $85.22. Nevro Corp. has a 12 month low of $65.82 and a 12 month high of $106.93.

Nevro Corp. (NYSE:NVRO) last announced its quarterly earnings data on Monday, August 7th. The medical equipment provider reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by $0.11. Nevro Corp. had a negative net margin of 14.33% and a negative return on equity of 16.25%. The company had revenue of $78.02 million for the quarter, compared to analysts’ expectations of $77.75 million. During the same period last year, the business earned ($0.31) earnings per share. The company’s quarterly revenue was up 40.8% compared to the same quarter last year. Equities analysts expect that Nevro Corp. will post ($1.17) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This piece of content was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/15/pioneer-investment-management-inc-sells-20803-shares-of-nevro-corp-nvro.html.

NVRO has been the subject of several recent analyst reports. Zacks Investment Research cut shares of Nevro Corp. from a “hold” rating to a “sell” rating in a research note on Thursday, May 11th. Northland Securities reaffirmed a “buy” rating and set a $96.00 price objective on shares of Nevro Corp. in a research note on Tuesday, May 9th. ValuEngine cut shares of Nevro Corp. from a “hold” rating to a “sell” rating in a research note on Wednesday, May 24th. Canaccord Genuity reaffirmed a “buy” rating and set a $120.00 price objective on shares of Nevro Corp. in a research note on Wednesday, July 5th. Finally, BidaskClub raised shares of Nevro Corp. from a “sell” rating to a “hold” rating in a research note on Sunday, July 16th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company. Nevro Corp. has an average rating of “Hold” and an average price target of $100.57.

Nevro Corp. Company Profile

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Want to see what other hedge funds are holding NVRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nevro Corp. (NYSE:NVRO).

Institutional Ownership by Quarter for Nevro Corp. (NYSE:NVRO)

Receive News & Stock Ratings for Nevro Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp. and related stocks with our FREE daily email newsletter.